<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378338</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-GKR-ATC-2011/1</org_study_id>
    <nct_id>NCT01378338</nct_id>
  </id_info>
  <brief_title>Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational</brief_title>
  <acronym>Refresh</acronym>
  <official_title>Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD
      in Korea-an observational study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrence after treatment with PPI in patients with GERD</measure>
    <time_frame>12month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate to the treatment with PPI in patients with GERD</measure>
    <time_frame>12month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics related to the recurrence of GERD</measure>
    <time_frame>12month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete resolution in each group of patients with ERD or NERD</measure>
    <time_frame>12month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrence in each group of patients with ERD or NERD</measure>
    <time_frame>12month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by EQ-5D and WPAI-GERD in each group of patients with ERD or NERD</measure>
    <time_frame>12month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">855</enrollment>
  <condition>The Aim of This Study is to Investigate the Frequency and Related Risk Factors of Recurrence, and Quality of Life in Patients With GERD After Treatment With PPI</condition>
  <arm_group>
    <arm_group_label>Typical reflux symptom by EGD</arm_group_label>
    <description>Total 2000 subjects who has Typical reflux symptom by EGD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with typical reflux symptoms (heartburn or regurgitation) undergone upper
        endoscopy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both ERD or NERD patient who confirmed by EGD findings within 12 months prior to V1
             and have a symptom with moderate or more, at least once per week within 1 week prior
             to V1 and Patients between age 20 and 80with typical reflux symptoms

          -  Among the patient who have not taken PPI or H2 blocker within 4 weeks prior to V1,
             needs to be prescribed PPIs 4~8 weeks as a part of the routine clinical practice due
             to typical symptom

          -  Patients who give the signed informed consent

        Exclusion Criteria:

          -  Patients with past history of gastrointestinal surgery

          -  Patients with known malignancy or history of such diseases

          -  Patients with moderate to severe general medical conditions like ischemic heart
             disease, chronic renal failure, congestive heart failure, COPD, liver cirrhosis, acute
             or chronic pancreatitis, or other medical conditions which the investigator considers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HyeWon Koo</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeonju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>Comparison between ERD and NERD</keyword>
  <keyword>Rate of complete resolution</keyword>
  <keyword>rate of recurrence</keyword>
  <keyword>QOL</keyword>
  <keyword>To investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI</keyword>
  <keyword>The aim of this study is to investigate the frequency and related risk factors of recurrence, and quality of life in patients with GERD after treatment with PPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

